NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong

August 18, 2026

NextCell Pharma AB ("NextCell" or the "Company") has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. In parallel, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), effective 1 September. NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026, held 9–12 September.

The EU-Japan Biotech Business Mission focuses on business development and partnering between European and Japanese life science companies. The programme begins in September with digital business training, market intelligence and online partnering. The focus will be on activities in Japan 5–9 October, including the EU-Japan Biotech & Pharma Partnering Conference in Osaka and participation in BioJapan in Yokohama.

The selection follows NextCell’s participation in the first round of the Japan Entry Acceleration Program (JEAP), initiated and funded by the Japan External Trade Organization (JETRO). NextCell was one of only ten companies globally, and the only Swedish company, selected for the programme’s first cohort. Following the completion of JEAP, NextCell was encouraged by JETRO to apply for the EU-Japan Biotech Business Mission.

NextCell’s activities in Japan have provided the Company with access to industry and regulatory stakeholders and a deeper understanding of potential development pathways for NXTCL-T1D. Discussions with, among others, the PMDA, regulatory advisors and industry stakeholders have also provided greater clarity on potential models for future development and commercialisation, including the possibility of retaining manufacturing outside Japan.

In Hong Kong, NextCell has previously established the wholly owned subsidiary NextCell Hong Kong Limited as part of the Company’s strategy for Asia. NextCell is also a member of the Swedish Chamber of Commerce in Hong Kong and the Hong Kong Chamber of Commerce in Sweden. The office and membership in HSITP now represent a further step in strengthening the Company’s local presence.

“Over the past year, we have implemented our Asia strategy step by step. Our activities in Japan and Hong Kong have provided us with concrete regulatory and industry contacts, strengthened our network and clarified potential pathways for further development and commercialisation. The next step is to translate these efforts into partnerships for NXTCL in Asia,” says Mathias Svahn, CEO of NextCell.

For more information, please contact:
Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 (0)8-735 55 95
E-mail: info@nextcellpharma.com

Website:: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Nordic Growth AB is the company´s Certified Adviser.

About NextCell Pharma AB
NextCell is a clinical-stage cell therapy company developing the proprietary NXTCL™ platform for the treatment of immune-mediated diseases, with a primary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic cell therapies with controlled immunomodulation, consistent potency and scalable manufacturing. The company’s lead program in type 1 diabetes has shown potential to preserve insulin production and slow disease progression for several years after a single treatment. The group also includes the wholly owned subsidiaries NextCell Sverige, NextCell Hongkong, Cellaviva and QVance. The company was founded in 2014 and is headquartered in Huddinge next to the Karolinska University Hospital.

Download attachmentRead full press release on Cision (external link)
2018-08-17
NextCell’s partner PBKM exercises its TO 1 warrants
Stem cell company NextCell Pharma AB ("NXTCL") announces today that its shareholder and partner Polski Bank Komorek Macierzystych S.A. ("PBKM") is exercising all of its 320,000 warrants. This represents an investment of MSEK 1.6, corresponding to approximately 11 % of the outstanding series TO 1 warrants. The subscription period of the series TO 1 warrants runs from 23rd of August – 13th of September 2018. PBKM is one of Europe's leading players in the field of stem cells and is also contracted for the manufacturing of NXTCL's drug candidate ProTrans. PBKM is thus an important partner of
Stem cell company NextCell Pharma AB ("NXTCL") announces today that its shareholder and partner Polski Bank Komorek Macierzystych S.A. ("PBKM") is exercising all of its 320,000 warrants. This represents an investment of MSEK 1.6, corresponding to approximately 11 % of the outstanding series TO 1 ...
Read moreRead more
2018-08-13
An additional batch of ProTrans is released prior to use in NextCell Pharma’s ongoing clinical trial.
Stem cell company NextCell Pharma AB ("NextCell") hereby announces that it has received another batch of ProTrans for clinical use. ProTrans is manufactured according to GMP (Good Manufacturing Practices) and the stem cells are selected with the company's selection algorithm to ensure quality. The selection is carried out by NextCell and the large-scale production is then produced by supplier and shareholder Polski Bank Komorek Macierzystych S.A. ("PBKM"). The delivery is intended for use in the second part of the company's ongoing Phase I/II trial with ProTrans, which includes a total of 15
Stem cell company NextCell Pharma AB ("NextCell") hereby announces that it has received another batch of ProTrans for clinical use. ProTrans is manufactured according to GMP (Good Manufacturing Practices) and the stem cells are selected with the company's selection algorithm to ensure quality. Th...
Read moreRead more
2018-07-31
NextCell Pharma publishes quarterly report three 2017/2018
NextCell Pharma AB (”NXTCL”, “NextCell”) today, released its third quarter report 2017/2018 (September 2017 – May 2018). Nine Months (2017-09-01 until 2018-05-31)  · Net sales amounted to SEK 527 545 (318 438). · Operating result amounted to SEK -10 610 012 (-8 477 749).                      · Result per share* amounted to SEK -1,25 (-2,89). · Cash and bank amounted to SEK 5 929 492 (6 558 898). · Solidity amounted to 83.8 (70.4)%. · Net sales amounted to SEK 136 341 (197 846). · Operating result amounted to SEK -3 085 756 (-3 614 243).                        ·
NextCell Pharma AB (”NXTCL”, “NextCell”) today, released its third quarter report 2017/2018 (September 2017 – May 2018). Nine Months (2017-09-01 until 2018-05-31)  · Net sales amounted to SEK 527 545 (318 438). · Operating result amounted to SEK -10 610 012 (-8 477 749).                     ...
Read moreRead more
2018-07-30
NextCell Pharma introduces stem cell service for adults
Stem cell company NextCell Pharma AB (“NXTCL”) announces that it is preparing to launch a service for saving adipose (fat) tissue derived stem cells during the first half of 2019. The service allows adults to save their own stem cells for future use. The stem cells are collected by liposuction, purified, processed and frozen in liquid nitrogen. The effort is made in the light of the rapid development of techniques for differentiation of induced pluripotent stem cells, iPS cells, as well as regeneration of tissues for treatment in a variety of indications. NXTCL is first in Sweden to offer
Stem cell company NextCell Pharma AB (“NXTCL”) announces that it is preparing to launch a service for saving adipose (fat) tissue derived stem cells during the first half of 2019. The service allows adults to save their own stem cells for future use. The stem cells are collected by liposuction, p...
Read moreRead more
2018-07-18
NextCell celebrates its first-year anniversary as a listed company
The potential market for stem cell therapies is immense and development is at record speed. On July 13, 2017, stem cell company NextCell Pharma AB ("NextCell") was listed on Spotlight Stock Market (formerly AktieTorget). In his own words, CEO Mathias Svahn reflects on the company’s first year as a listed company and sends a reminder regarding the company's upcoming option redemption period. "We have promised a lot - we delivered even more. In the spring of 2017, we turned to you, our shareholders and asked for your investment to enable us to develop an advanced stem cell therapy which is
The potential market for stem cell therapies is immense and development is at record speed. On July 13, 2017, stem cell company NextCell Pharma AB ("NextCell") was listed on Spotlight Stock Market (formerly AktieTorget). In his own words, CEO Mathias Svahn reflects on the company’s first year as ...
Read moreRead more
2018-07-09
Publication of scientific article regarding the clinical trial with ProTrans
The stem cell company NextCell Pharma AB ("NXTCL") today announced, that a scientific article describing the ongoing clinical trial with ProTrans has been published in Clinical Trials in Degenerative Diseases (CTDD), a peer reviewed journal encompassing clinical trials, research, therapeutics and education within the field of degenerative diseases. The scientific article was written by Per-Ola Carlsson, principal investigator of the ongoing clinical study with ProTrans and Mathias Svahn, CEO of NXTCL The title of the article is: “Wharton’s jelly derived allogeneic mesenchymal stromal cells
The stem cell company NextCell Pharma AB ("NXTCL") today announced, that a scientific article describing the ongoing clinical trial with ProTrans has been published in Clinical Trials in Degenerative Diseases (CTDD), a peer reviewed journal encompassing clinical trials, research, therapeutics and...
Read moreRead more
2018-07-03
NextCell applies for prediction methodology patent
The stem cell company NextCell Pharma AB ("NXTCL") has submitted another patent application. This time regarding a method for predicting if a specific patient is susceptible to treatment with the drug candidate ProTrans. Since the beginning of 2017, NXTCL has performed preclinical experiments in parallel with the ongoing clinical trial with ProTrans, for the treatment of diabetes. The purpose of these experiments was in part to predict, in advance, whether ProTrans treatment should be beneficial for a particular patient. The patent application describes how to isolate the patient's immune
The stem cell company NextCell Pharma AB ("NXTCL") has submitted another patent application. This time regarding a method for predicting if a specific patient is susceptible to treatment with the drug candidate ProTrans. Since the beginning of 2017, NXTCL has performed preclinical experiments in ...
Read moreRead more
2018-06-29
The Data and Safety Monitoring Board approves the usage of high-dose ProTrans in the ongoing clinical trial
Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the high-dose cohort. The treatment of all three patients in the medium-dose cohort with ProTrans has been assessed as safe using a one-month follow-up period. Now NXTCL is now able to recruit patients for the last dose cohort, which is the high-dose cohort. The recruitment of the last dose cohort is expected to take one
Stem cell company NextCell Pharma AB ("NXTCL") announces today that the Data and Safety Monitoring Board for the clinical trial using ProTrans has given its approval for the principal investigator professor Per-Ola Carlsson and NextCell to proceed and treat 3 patients in the high-dose cohort. The...
Read moreRead more